[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Schiffer, 2011 - Google Patents

Imaging in neurology research III: focus on neurotransmitter imaging

Schiffer, 2011

Document ID
94487881100201161
Author
Schiffer W
Publication year
Publication venue
Small Animal Imaging: Basics and Practical Guide

External Links

Snippet

Small animal PET is one of the most recently developed and rapidly evolving areas of biomedical imaging, with applications ranging from drug development to the study of molecular events associated with normal and abnormal thought and behavior. The aim of …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
DeLorenzo et al. In vivo ketamine-induced changes in [11C] ABP688 binding to metabotropic glutamate receptor subtype 5
Parsey et al. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C] DASB and positron emission tomography
Hillmer et al. Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (−)-[18F] Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain
Ichise et al. Linearized reference tissue parametric imaging methods: application to [11C] DASB positron emission tomography studies of the serotonin transporter in human brain
Bohnen et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease
Jones et al. The development, past achievements, and future directions of brain PET
Montgomery et al. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C] FLB 457 PET
Willeit et al. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO
Schneier et al. Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings
Seneca et al. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S, S)-[18 F] FMeNER-D 2
Kim et al. In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [18F] FE-PE2I
Kegeles et al. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F] fallypride positron emission tomography
Koeppe et al. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-α-[11C] dihydrotetrabenazine (DTBZ) and positron emission tomography
DeLorenzo et al. Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [11C] ABP688
Sander et al. News and views on in vivo imaging of neurotransmission using PET and MRI
US20100312105A1 (en) Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
Asselin et al. Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [11C] FLB 457: re-evaluation of the validity of using a cerebellar reference region
Lundberg et al. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram
Erlandsson et al. Measuring SSRI occupancy of SERT using the novel tracer [123 I] ADAM: a SPECT validation study
Wyss et al. Stimulation-induced increases of astrocytic oxidative metabolism in rats and humans investigated with 1-11C-acetate
Varrone et al. Human brain imaging of dopamine transporters
Hinz et al. Validation of a tracer kinetic model for the quantification of 5-HT2A receptors in human brain with [11C] MDL 100,907
Girgis et al. Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study
Phan et al. Quantification of [11C] yohimbine binding to α2 adrenoceptors in rat brain in vivo
Lehto et al. Sensitivity of [11 C] ORM-13070 to increased extracellular noradrenaline in the CNS–a PET study in human subjects